"The PEI is supportive of Immutep moving into a registrational trial in first line NSCLC and evaluating efti in
combination with an anti-PD-1 therapy in a chemotherapy-free regimen or as a triple combination approach
that includes chemotherapy. Also, the PEI acknowledged the good safety profile of efti in combination with
anti-PD-1 therapy."
wonder what immutep's intent is, wonder if they will proceed with both therapys in different trials if approved?..
Ann: PEI provides constructive feedback for ph3 lung cancer trial, page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
43.5¢ |
Change
-0.010(2.25%) |
Mkt cap ! $517.1M | |||
| Open | High | Low | Value | Volume |
| 44.0¢ | 45.0¢ | 43.0¢ | $618.8K | 1.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 21064 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.0¢ | 1500 | 1 |
View Market Depth
| Last trade - 16.10pm 16/05/2024 (20 minute delay) ? |
|
|||||
|
Last
44.0¢ |
Change
-0.010 ( 2.68 %) |
||||
| Open | High | Low | Volume | ||
| 44.0¢ | 45.0¢ | 43.0¢ | 344370 | ||
| Last updated 15.59pm 16/05/2024 ? | |||||
| IMM (ASX) Chart |